EMG
BBIO icon

ETF Managers Group’s BridgeBio Pharma BBIO Stock Holding History

ETF Managers Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$225K Buy
+13,597
New +$159K 0.01% 575

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
AIG
American International Group New York $2.93M AUM 12.08% 1-Year Est. Return

ETF Managers Group's BBIO Position: Q1 2023 in Review

ETF Managers Group opened a new position in BridgeBio Pharma (BBIO) in Q1 2023: 13,597 shares worth $225K. The stake represents 0.01% of the portfolio and ranks #575 among its holdings.

213 funds tracked by Wall St. Rank hold BBIO as of Q1 2023.

  • ETF Managers Group held 13,597 shares of BridgeBio Pharma worth $225K as of Q1 2023.
  • BridgeBio Pharma was a new ETF Managers Group position in Q1 2023.
  • BridgeBio Pharma made up 0.01% of ETF Managers Group's portfolio in Q1 2023, its #575 holding.
  • 213 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.